Why GlaxoSmithKline plc and BTG plc are the perfect prescription for growth and income!

Bilaal Mohamed explains why GlaxoSmithKline plc (LON: GSK) and BTG plc (LON: BTG) could be a great pairing for investors looking for defensive stability AND exciting growth potential from pharmaceuticals.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’ll be explaining why I think GlaxoSmithKline (LSE: GSK) and BTG (LSE: BTG) could provide the perfect balance of defensive income AND exciting growth potential for investors looking to gain exposure to the pharmaceuticals sector.

Growth at a very reasonable price

Specialist healthcare firm BTG has enjoyed phenomenal success in recent years with revenues and earnings rising steeply since the start of the decade. Indeed, underlying earnings per share have doubled from 11.4p in 2012 to 21.9p reported recently for FY2016. Annual results to the end of March revealed a doubling of pre-tax profits to £57.5m, compared to the £26.7m reported a year earlier, with revenues rising 22% year-on-year to £447.5m.

The FTSE 250 company is making good progress in implementing its growth strategy, which centres around geographic expansion, product innovation and ‘indication expansion’. BTG is also expanding its portfolio through M&A activity, with the recent acquisition of US-based Galil Medical cementing the company’s leadership in interventional oncology.

The City expects BTG’s growth story to continue, with analysts talking about an 8% rise in earnings this year to £91m, with a further 30% improvement pencilled-in for FY2018. This would leave the shares trading on a price-to-earnings ratio (P/E) of just 22 for the year to March 2018, which is well below historical levels for this classic growth stock. For me, BTG offers significant upside potential for investors looking for growth at a very reasonable price.

Breath easier with Glaxo

Blue chip drugs giant GlaxoSmithKline had something to cheer about last week when it announced positive results from the Salford lung study for the company’s Relvar Ellipta treatment for COPD (chronic obstructive pulmonary disease). COPD includes chronic bronchitis and emphysema, and affects around 3m people in the UK alone. Small victories like this are important for the long-term future of large drugmakers such as Glaxo that have been affected by patent expiries and generic competition for some of its treatments.

However, although not completely unscathed, Glaxo has been less affected than some of its rivals. And with a strong pipeline of drugs in research & development, it should give investors some confidence about the company’s longer-term prospects. The medium-term outlook looks promising too, with consensus forecasts suggesting a healthy 16% rise in underlying profits to £4.27bn this year, followed by a further 4% improvement to £4.46bn in 2017.

Glaxo currently trades at fair value in my opinion, with a forward P/E of 17 for this year, falling to 16 in 2017, which is on a par with the recent past. But investment in Glaxo is always about the dividend, and the company continues to reward shareholders with prospective yields of around 5.5% forecast until 2019. Attractions remain for investors looking for high-income low-risk exposure to the pharmaceuticals sector, and Glaxo nicely offsets the risks associated with high-growth plays such as BTG.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »